AIDS-associated cryptococcosis: A comparison of epidemiology, clinical features and outcome in the pre- and post-HAART eras. Experience of a single centre in Italy

HIV Medicine

Volumn 10, Issue 1, 2009, Pages 6-11

  Antinori, Spinello ^a   Ridolfo, A L ^a   Fasan, M ^a   Magni, C ^a   Galimberti, L ^a   Milazzo, L ^a   Sollima, S ^a   Adorni, F ^b   Giuliani, G ^a   Galli, M ^a   Corbellino, M ^a   Parravicini, C ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b CNR   (Italy)

Author keywords

Cryptococcosis; HIV; Post HAART; Pre HAART; Survival

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; ASEPTIC MENINGITIS; BLOOD TRANSFUSION; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID CULTURE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; DISEASE ASSOCIATION; FEMALE; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUALITY; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INTRAVENOUS DRUG ABUSE; ITALY; LYMPHADENITIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; RISK FACTOR; SKIN ABSCESS; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CRYPTOCOCCOSIS; FEMALE; HIV-1; HOSPITALIZATION; HUMANS; ITALY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; VIRAL LOAD; YOUNG ADULT;

EID: 58049192375     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00645.x     Document Type: Article

References (25)

1. Sacktor N, Lyles RH, Skolasky R et al. HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990-1998. Neurology 2001; 56: 257-260.
2. d'Arminio Monforte A, Cinque P, Mocroft A et al. Changing incidence of CNS HIV-related diseases in the EuroSIDA cohort. Ann Neurol 2004; 55: 320-328.
3. Dromer F, Mathoulin-Pelissier S, French Cryptococcosis Study Group et al. Determinants of disease presentation and outcome during cryptococcosis: The Crypto A/D StuEy. PLoS Med 2007; 4: e21.
4. Dromer F, Mathoulin-Pelissier S, Fontanet A et al. Epidemiology of HIV-associated cryptococcosis in France (1985-2001): Comparison of the pre-HAART and post-HAART eras. AIDS 2004; 18: 555-562.
5. van Elden LJR, Walenkamp AME, Lipovsky MM et al. Declining number of patients with cryptococcosis in the Netherlands in the era of highly active antiretroviral therapy. AIDS 2000; 14: 2787-2800.
6. McCarthy KM, Morgan J, Wannemuehler KA et al. Population-based surveillance for cryptococcosis in an antiretroviral-naïve South African province with high seroprevalence. AIDS 2006; 20: 2199-2206.
7. Hakim JG, Gangaidzo IT, Heyderman RS et al. Impact of HIV infection on meningitis in Harare, Zimbabwe: A prospective study of 406 predominantly adult patients. AIDS 2000; 14: 1401-1407.
8. Scarborough M, Gordon SB, Whitty CJM et al. Corticosteroids for bacterial meningitis in adults in Sub-Saharan Africa. N Engl J Med 2007; 357: 2441-2450.
9. Manfredi R, Calza L, Chiodo F. AIDS-associated cryptococcus infection before and after the highly active antiretroviral therapy era: Emerging management problems. Int J Antimicrob Agents 2003; 22: 449-452.
10. Lortholary O, Poizat G, Zeller V et al. Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS 2006; 20: 2183-2191.
11. Asciouglu S, Rex JH, Bennett JE et al. Defining opportunistic fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplantation: An international consensus. Clin Infect Dis 2002; 34: 7-14.
12. Antinori S, Galimberti L, Magni C et al. Cryptococcus neoformans infection in a cohort of Italian AIDS patients: Natural history, early prognostic parameters and autopsy findings. Eur J Clin Microbiol Infect Dis 2001; 20: 711-717.
13. Centro Operativo AIDS. Aggiornamento dei casi di AIDS e delle nuove diagnosi di infezione da HIV (Update of AIDS cases and new HIV infection diagnosis). Notiziario dell'Istituto Superiore di Sanità 2006; 19: S1-S24.
14. Galli M, Esposito R, Antinori S et al. HIV-1 infection, tuberculosis and syphilis in male transsexual prostitutes in Milan, Italy. J Acquir Immune Defic Syndr 1991; 4: 1006-1007.
15. Spizzichino L, Zaccarelli M, Rezza G, Ippolito G, Antinori A, Gattari P. HIV infection among foreign transsexual sex workers in Rome: Prevalence, behaviour patterns and seroconversion rates. Sex Transm Dis 2001; 28: 405-411.
16. Castelnuovo B, Chiesa E, Rusconi S et al. Declining incidence of AIDS and increasing prevalence of AIDS presenters among AIDS patients in Italy. Eur J Clin Microbiol Infect Dis 2003; 22: 663-669.
17. Jenny-Avital ER, Abadi M. Immune reconstitution cryptococcosis after initiation of successful highly active antiretroviral therapy. Clin Infect Dis 2002; 35: E128-e133.
18. Lortholary O, Fontanet A, for the French Cryptococcosis Study Group et al. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 2005; 19: 1043-1049.
19. Martinez E, Garcia-Viejo MA, Marcos MA et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in HIV-infected patients responding to highly active antiretroviral therapy. AIDS 2000; 14: 2615-2617.
20. Nwokolo NC, Fischer M, Gazzard BG, Nelson MR. Cessation of secondary prophylaxis in patients with cryptococcosis. AIDS 2001; 15: 1438-1439.
21. Aberg JA, Price RW, Heeren DM, Bredt B. A pilot study of the discontinuation of antifungal therapy for disseminated cryptococcal disease in patients with acquired immunodeficiency syndrome, following immunologic response to antiretroviral therapy. J Infect Dis 2002; 185: 1179-1182.
22. Kirk O, Reiss P, Uberti-Foppa C et al. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med 2002; 137: 239-250.
23. Vibhagool A, Sungkanuparph S, Mootsikapun P et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: A prospective, multicenter, randomized study. Clin Infect Dis 2003; 36: 1329-1331.
24. Mussini C, Pezzotti P, Miro JM et al. Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: An international observational study. Clin Infect Dis 2004; 38: 565-571.
25. Antinori S. Molluscum or a mimic? Add Penicillium marneffei. Am J Med 2007; 120: E19-e20.